Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 682

1.

Biologic response to subcutaneous and intranasal therapy with desmopressin in a large Amish kindred with Type 2M von Willebrand disease.

Sharthkumar A, Greist A, Di Paola J, Winay J, Roberson C, Heiman M, Herbert S, Parameswaran R, Shapiro A.

Haemophilia. 2008 May;14(3):539-48. doi: 10.1111/j.1365-2516.2008.01666.x. Epub 2008 Feb 25.

PMID:
18312368
3.

Laboratory diagnosis and molecular classification of von Willebrand disease.

Gadisseur A, Hermans C, Berneman Z, Schroyens W, Deckmyn H, Michiels JJ.

Acta Haematol. 2009;121(2-3):71-84. doi: 10.1159/000214846. Epub 2009 Jun 8. Review.

PMID:
19506352
4.

Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.

Michiels JJ, van de Velde A, van Vliet HH, van der Planken M, Schroyens W, Berneman Z.

Semin Thromb Hemost. 2002 Apr;28(2):111-32.

PMID:
11992235
5.

Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.

Michiels JJ, van Vliet HH, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U.

Clin Appl Thromb Hemost. 2007 Jan;13(1):14-34. Review.

PMID:
17164493
6.

Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?

Favaloro EJ, Thom J, Patterson D, Just S, Dixon T, Koutts J, Baccala M, Rowell J, Baker R.

Thromb Res. 2009 Apr;123(6):862-8. doi: 10.1016/j.thromres.2008.10.008. Epub 2008 Dec 7.

PMID:
19064279
7.

Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.

Gadisseur A, van der Planken M, Schroyens W, Berneman Z, Michiels JJ.

Acta Haematol. 2009;121(2-3):145-53. doi: 10.1159/000214855. Epub 2009 Jun 8. Review.

PMID:
19506361
8.

Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.

Michiels JJ, Gadisseur A, Budde U, Berneman Z, van der Planken M, Schroyens W, van de Velde A, van Vliet H.

Semin Thromb Hemost. 2005 Nov;31(5):577-601. Review.

PMID:
16276467
9.

Evaluation of desmopressin effects on haemostasis in children with congenital bleeding disorders.

Hanebutt FL, Rolf N, Loesel A, Kuhlisch E, Siegert G, Knoefler R.

Haemophilia. 2008 May;14(3):524-30. doi: 10.1111/j.1365-2516.2008.01672.x. Epub 2008 Feb 18.

PMID:
18284449
10.

Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study.

Federici AB, Mazurier C, Berntorp E, Lee CA, Scharrer I, Goudemand J, Lethagen S, Nitu I, Ludwig G, Hilbert L, Mannucci PM.

Blood. 2004 Mar 15;103(6):2032-8. Epub 2003 Nov 20.

11.

Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).

Michiels JJ, Berneman ZN, van der Planken M, Schroyens W, Budde U, van Vliet HH.

Blood Coagul Fibrinolysis. 2004 Jun;15(4):323-30.

PMID:
15166918
12.
13.

Intranasal administration of demopressin (DDAVP) for type 1 and type 2A von Willebrand disease.

Mohri H, Hashimoto Y, Yamazaki E, Kanamori H, Okubo T.

Hematopathol Mol Hematol. 1998;11(2):109-15.

PMID:
9608359
14.

Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.

Favaloro EJ, Lloyd J, Rowell J, Baker R, Rickard K, Kershaw G, Street A, Scarff K, Barrese G, Maher D, McLachlan AJ.

Thromb Haemost. 2007 Jun;97(6):922-30.

PMID:
17549293
15.

Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD.

Castaman G, Lethagen S, Federici AB, Tosetto A, Goodeve A, Budde U, Batlle J, Meyer D, Mazurier C, Fressinaud E, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Pasi J, Hill F, Peake I, Rodeghiero F.

Blood. 2008 Apr 1;111(7):3531-9. doi: 10.1182/blood-2007-08-109231. Epub 2008 Jan 29.

16.

Laboratory response to intranasal desmopressin in women with menorrhagia and platelet dysfunction.

Rose SS, Faiz A, Miller CH, Saidi P, Philipp CS.

Haemophilia. 2008 May;14(3):571-8. doi: 10.1111/j.1365-2516.2008.01655.x. Epub 2008 Feb 27.

PMID:
18312366
17.

Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.

Michiels JJ, Gadisseur A, Vangenegten I, Schroyens W, Berneman Z.

Acta Haematol. 2009;121(2-3):119-27. doi: 10.1159/000214852. Epub 2009 Jun 8. Review.

PMID:
19506358
18.

Laboratory diagnosis and molecular basis of mild von Willebrand disease type 1.

Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van Vliet HH.

Acta Haematol. 2009;121(2-3):85-97. doi: 10.1159/000214847. Epub 2009 Jun 8. Review.

PMID:
19506353
19.

Supplemental Content

Support Center